Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;18(5):657-664.
doi: 10.1038/s41397-018-0040-6. Epub 2018 Aug 31.

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

Affiliations

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

Jonathan Massey et al. Pharmacogenomics J. 2018 Sep.

Abstract

Rheumatoid arthritis (RA) is characterised by chronic synovial joint inflammation. Treatment has been revolutionised by tumour necrosis factor alpha inhibitors (TNFi) but each available drug shows a significant non-response rate. We conducted a genome-wide association study of 1752 UK RA TNFi-treated patients to identify predictors of change in the Disease Activity Score 28 (DAS28) and subcomponents over 3-6 months. The rs7195994 variant at the FTO gene locus was associated with infliximab response when looking at a change in the swollen joint count (SJC28) subcomponent (p = 9.74 × 10-9). Capture Hi-C data show chromatin interactions in GM12878 cells between rs2540767, in high linkage disequilibrium with rs7195994 (R2 = 0.9) and IRX3, a neighbouring gene of FTO. IRX3 encodes a transcription factor involved in adipocyte remodelling and is regarded as the obesity gene at the FTO locus. Importantly, the rs7195994 association remained significantly associated following adjustment for BMI. In addition, using capture Hi-C data we showed interactions between TNFi-response associated variants and 16 RA susceptibility variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment in

Similar articles

Cited by

References

    1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41:793–800. - PubMed
    1. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27–39. - PubMed
    1. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s) Microsc Res Tech. 2000;50:184–95. - PubMed
    1. Plenge RM, Bridges SL., Jr. Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum. 2011;63:590–3. - PMC - PubMed
    1. Barton A, Pitzalis C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatology. 2016;56:1247–50. - PMC - PubMed

Publication types

Substances